» Articles » PMID: 27403302

Determinants of Esophageal Varices Bleeding in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Overview
Publisher Wiley
Specialty Gastroenterology
Date 2016 Jul 13
PMID 27403302
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), yet treatment safety may be challenged by portal hypertension. We therefore assessed the prevalence, risk factors and clinical consequences of esophageal varices (EVs) in sorafenib-treated patients with HCC.

Methods: Starting in 2008, all compensated patients with advanced or intermediate HCC not eligible for other therapies were consecutively enrolled in a prospective evaluation of sorafenib therapy, all with pretreatment by upper-gastrointestinal endoscopy (UGE).

Results: A total of 150 patients received sorafenib for 4.6 (95% CI, 3.3-5.6) months. At baseline, 61 (41%) patients were EV free (group A), 78 (52%) had EVs (61 small EVs (group B), 17 medium/large EVs (group C)) and 11 (7%) previously endoscopically treated EVs (group D). Propranolol was given to all patients with medium/large EVs and those with previous bleeding. Twelve patients (8%) bled from EVs after 36 (18-260) days of sorafenib. During sorafenib, bleeding occurred in six of 26 group B patients with neoplastic portal vein thrombosis (nPVT), three of nine group C patients with nPVT, two of five group D patients with nPVT and one of six without nPVT (p < 0.0001), nPVT being the strongest independent predictor of bleeding by multivariate analysis (HR = 15.4, 95% CI 1.84-129.6).

Conclusion: UGE screening is worthwhile in HCC patients allocated to sorafenib since it identifies patients with EVs at risk of bleeding during therapy, particularly those with nPVT.

Citing Articles

Validation of a Machine Learning Algorithm, EVendo, for Predicting Esophageal Varices in Hepatocellular Carcinoma.

Yang J, Chittajallu P, Benhammou J, Patel A, Pisegna J, Tabibian J Dig Dis Sci. 2024; 69(8):3079-3084.

PMID: 38896359 PMC: 11341647. DOI: 10.1007/s10620-024-08449-y.


Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.

Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C Liver Cancer. 2024; 13(2):215-226.

PMID: 38751557 PMC: 11095591. DOI: 10.1159/000534127.


Complications of immunotherapy in advanced hepatocellular carcinoma.

Song Y, Yoo J, Kim S, Kim Y J Liver Cancer. 2023; 24(1):9-16.

PMID: 38018074 PMC: 10990673. DOI: 10.17998/jlc.2023.11.21.


Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma.

Wu C, Lui R, Wong V, Yam T, Yip T, Liu K Cancers (Basel). 2023; 15(9).

PMID: 37173947 PMC: 10177352. DOI: 10.3390/cancers15092480.


Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.

Suzuki H, Iwamoto H, Shimose S, Niizeki T, Shirono T, Noda Y Front Oncol. 2022; 12:948293.

PMID: 35936693 PMC: 9355247. DOI: 10.3389/fonc.2022.948293.


References
1.
Elice F, Jacoub J, Rickles F, Falanga A, Rodeghiero F . Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol. 2008; 83(11):862-70. DOI: 10.1002/ajh.21277. View

2.
Siegel A, Cohen E, Ocean A, Lehrer D, Goldenberg A, Knox J . Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26(18):2992-8. PMC: 3635806. DOI: 10.1200/JCO.2007.15.9947. View

3.
Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

4.
Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C . Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003; 38(3):266-72. DOI: 10.1016/s0168-8278(02)00420-8. View

5.
Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View